Astellas Expands Oncology Pipeline Through Partnership with Vir Biotechnology
Astellas Pharma Inc. and Vir Biotechnology, Inc. announced they have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN® dual-masked CD3 T-cell engager (TCE) targeting PSMA for the treatment of prostate cancer. The collaboration aims to accelerate the development of VIR-5500…
